• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

连续分析帕金森病和非典型帕金森综合征患者的脑脊液轴突和神经胶质标志物。

Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders.

机构信息

Department of Neurology, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden.

出版信息

Parkinsonism Relat Disord. 2010 Feb;16(2):142-5. doi: 10.1016/j.parkreldis.2009.07.007. Epub 2009 Jul 31.

DOI:10.1016/j.parkreldis.2009.07.007
PMID:19647470
Abstract

Cerebrospinal fluid (CSF) levels of neurofilament light protein (NFL), a marker of neuronal damage, are normal in Parkinson's disease (PD) but elevated in multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). Therefore, CSF NFL can help differentiate between PD on one hand and MSA/PSP on the other. In the present study of 10 patients with PD, 21 with MSA, 14 with PSP, 11 with corticobasal degeneration (CBD), and 59 healthy controls, this previous observation is confirmed and also extended to include CBD by showing that similarly high CSF NFL levels are seen not only in MSA and PSP but also in CBD. CSF levels of glial fibrillary acidic protein (GFAP), a protein expressed mainly in fibrillary astrocytes, were similar in all investigated groups. In addition, consecutive analyses of CSF NFL and CSF GFAP levels showed relatively stable levels over time in all the investigated parkinsonian disorders, suggesting that the rate of neuronal degeneration is rather constant over time. Our results suggest that measurements of CSF NFL but not GFAP can be useful in the differential diagnosis of PD versus atypical parkinsonian disorders (APD). However they do not help differentiate between the different APD.

摘要

脑脊液(CSF)中的神经丝轻蛋白(NFL)水平,是神经元损伤的标志物,在帕金森病(PD)中正常,但在多系统萎缩(MSA)和进行性核上性麻痹(PSP)中升高。因此,CSF NFL 有助于区分 PD 与 MSA/PSP。在本研究中,纳入了 10 名 PD 患者、21 名 MSA 患者、14 名 PSP 患者、11 名皮质基底节变性(CBD)患者和 59 名健康对照者。该研究证实了之前的观察结果,并扩展至包括 CBD,表明不仅在 MSA 和 PSP 中,而且在 CBD 中也观察到同样高的 CSF NFL 水平。脑脊液中胶质纤维酸性蛋白(GFAP)水平,主要在纤维星形胶质细胞中表达,在所有研究组中相似。此外,对 CSF NFL 和 CSF GFAP 水平的连续分析表明,所有研究的帕金森病中 CSF NFL 和 CSF GFAP 水平随时间相对稳定,提示神经元退化的速度随时间相对恒定。我们的研究结果表明,CSF NFL 而非 GFAP 的测量值可有助于 PD 与非典型帕金森病(APD)的鉴别诊断。但 CSF NFL 并不能帮助区分不同的 APD。

相似文献

1
Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders.连续分析帕金森病和非典型帕金森综合征患者的脑脊液轴突和神经胶质标志物。
Parkinsonism Relat Disord. 2010 Feb;16(2):142-5. doi: 10.1016/j.parkreldis.2009.07.007. Epub 2009 Jul 31.
2
Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.与帕金森病相比,进行性核上性麻痹和多系统萎缩患者脑脊液中神经丝蛋白水平升高。
Mov Disord. 1998 Jan;13(1):70-7. doi: 10.1002/mds.870130116.
3
Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes.脑脊液中的神经丝重链NfH(SMI35)有助于帕金森综合征的鉴别诊断。
Mov Disord. 2006 Dec;21(12):2224-7. doi: 10.1002/mds.21124.
4
Levels of brain related proteins in cerebrospinal fluid: an aid in the differential diagnosis of parkinsonian disorders.脑脊液中脑相关蛋白水平:有助于帕金森病的鉴别诊断。
Parkinsonism Relat Disord. 2009 Mar;15(3):205-12. doi: 10.1016/j.parkreldis.2008.05.001. Epub 2008 Jun 17.
5
Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis.脑脊液中神经丝轻链水平可区分帕金森病与非典型帕金森综合征:一项荟萃分析的证据
J Neurol Sci. 2015 May 15;352(1-2):84-7. doi: 10.1016/j.jns.2015.03.041. Epub 2015 Apr 7.
6
Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: A meta-analysis.脑脊液神经丝轻链蛋白在帕金森病性障碍鉴别诊断中的应用:一项荟萃分析
Neurosci Lett. 2018 Oct 15;685:35-41. doi: 10.1016/j.neulet.2018.07.030. Epub 2018 Jul 20.
7
Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.一组5种脑脊液生物标志物在痴呆和/或帕金森病患者鉴别诊断中的准确性
Arch Neurol. 2012 Nov;69(11):1445-52. doi: 10.1001/archneurol.2012.1654.
8
Differential pattern of brain-specific CSF proteins tau and amyloid-β in Parkinsonian syndromes.帕金森综合征患者脑特异性 CSF 蛋白 tau 和淀粉样-β的差异模式。
Mov Disord. 2010 Jul 15;25(9):1284-8. doi: 10.1002/mds.22895.
9
Proteomic profiling of cerebrospinal fluid in parkinsonian disorders.帕金森病患者脑脊液的蛋白质组学分析。
Parkinsonism Relat Disord. 2010 Sep;16(8):545-9. doi: 10.1016/j.parkreldis.2010.06.011.
10
Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy.脑脊液β淀粉样蛋白42在多系统萎缩中降低,但在帕金森病和进行性核上性麻痹中正常。
Mov Disord. 2003 Feb;18(2):186-90. doi: 10.1002/mds.10321.

引用本文的文献

1
Fluid biomarkers in atypical Parkinsonism: current state and future perspectives.非典型帕金森病中的体液生物标志物:现状与未来展望
J Neural Transm (Vienna). 2025 May 20. doi: 10.1007/s00702-025-02930-2.
2
Head-to-head comparison of four cerebrospinal fluid and three plasma neurofilament light chain assays in Parkinsonism.帕金森综合征中四种脑脊液和三种血浆神经丝轻链检测方法的直接比较
NPJ Parkinsons Dis. 2025 Apr 28;11(1):98. doi: 10.1038/s41531-025-00951-y.
3
Neurofilament Light Chain in Cerebrospinal Fluid and Blood in Multiple System Atrophy: A Systematic Review and Meta-Analysis.
多系统萎缩患者脑脊液和血液中的神经丝轻链:一项系统评价和荟萃分析
Brain Sci. 2025 Feb 25;15(3):241. doi: 10.3390/brainsci15030241.
4
GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA).胶质纤维酸性蛋白(GFAP)和神经丝轻链(NfL)作为多系统萎缩(MSA)临床疾病严重程度和疾病进展的生物标志物。
J Neurol. 2024 Oct;271(10):6991-6999. doi: 10.1007/s00415-024-12647-z. Epub 2024 Sep 10.
5
Global research trends on the links between NfL and neurological disorders: A bibliometric analysis and review.神经丝轻链(NfL)与神经系统疾病之间联系的全球研究趋势:文献计量分析与综述
Heliyon. 2024 Jul 19;10(15):e34720. doi: 10.1016/j.heliyon.2024.e34720. eCollection 2024 Aug 15.
6
Association of Neurofilament Light Chain, [F]PI-2620 Tau-PET, TSPO-PET, and Clinical Progression in Patients With β-Amyloid-Negative CBS.β-淀粉样蛋白阴性 CBS 患者中神经丝轻链、[F]PI-2620 Tau-PET、TSPO-PET 与临床进展的相关性。
Neurology. 2024 Jan 9;102(1):e207901. doi: 10.1212/WNL.0000000000207901. Epub 2023 Dec 14.
7
Multidimensional biomarkers for multiple system atrophy: an update and future directions.多维度生物标志物在多系统萎缩中的应用:更新与未来方向。
Transl Neurodegener. 2023 Jul 28;12(1):38. doi: 10.1186/s40035-023-00370-0.
8
Midbrain and pons MRI shape analysis and its clinical and CSF correlates in degenerative parkinsonisms: a pilot study.中脑和脑桥 MRI 形态分析及其在变性帕金森病中的临床和 CSF 相关性:一项初步研究。
Eur Radiol. 2023 Jul;33(7):4540-4551. doi: 10.1007/s00330-023-09435-0. Epub 2023 Feb 11.
9
Clinical Spectrum of Tauopathies.tau蛋白病的临床谱
Front Neurol. 2022 Jul 14;13:944806. doi: 10.3389/fneur.2022.944806. eCollection 2022.
10
Deep phenotyping for precision medicine in Parkinson's disease.深度表型分析在帕金森病精准医学中的应用。
Dis Model Mech. 2022 Jun 1;15(6). doi: 10.1242/dmm.049376.